Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure

To the Editor:

Pitt et al have concluded in their study that eplerenone should be prescribed to all of the postacute myocardial infarction patients with reduced left ventricular ejection fraction and heart failure. However, there are a few concerns in using eplerenone in certain populations.

During the development of heart failure, there is an activation of the renin-angiotensin-aldosterone system. This leads to the use of angiotensin-converting enzyme inhibitors as a core treatment modality for heart failure. In the late 1990s, the Randomized Aldactone Evaluation Study showed that the aldosterone receptor antagonist spironolactone decreased rehospitalization attributable to heart failure by 35%. The same authors noted reduced cardiovascular mortality in postmyocardial infarction patients when using eplerenone in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. These studies increased the prescription of aldosterone receptor antagonists and led to an increase in the incidence of hospitalizations attributable to hyperkalemia, especially in the elderly. This was particularly seen in patients with left ventricular ejection fraction <20%, on potassium supplements and concomitant usage of diuretics, along with lack of renal function monitoring. These episodes are also more frequent in patients with creatinine clearance <50 mL/min. In the United States, ~7.5 million elderly patients have creatinine clearance <60 mL/min. Renal function calculated using serum creatinine is misleading in elderly because of their decreased muscle mass. This is clearly evident in one of the reviews that actually showed a calculated glomerular filtration rate of <30 mL/min in patients with a baseline creatinine ≤1.8, who were prescribed aldosterone receptor antagonists. Therefore, the important message pertaining to elderly postmyocardial infarction patients is that glomerular filtration rate should be calculated before treating with eplerenone, because the drug may do more harm than benefit if not selectively prescribed.

Disclosures

None.

Radhakrishnan Ramaraj
Department of Internal Medicine
University of Arizona College of Medicine
Tucson, Ariz

Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure
Radhakrishnan Ramaraj

Hypertension. 2008;52:e147; originally published online October 20, 2008;
doi: 10.1161/HYPERTENSIONAHA.108.121509
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/52/6/e147

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/